Altered Cell Cycle Arrest by Multifunctional Drug-Loaded Enzymatically-Triggered Nanoparticles

Area of Science:

• Biomedical Engineering
• Nanomedicine
• Cancer Therapy

Background:

• Development of targeted nanoparticles for cancer treatment is crucial.
• Understanding drug-carrier interactions with cellular processes like the cell cycle is essential for efficacy.

Purpose of the Study:

• To develop and characterize cRGD-targeting nanoparticles (NPs-cRGD) loaded with Au-Pt(IV), PTX, and ADR.
• To investigate the impact of these drug-loaded NPs-cRGD on cancer cell cycle progression and cytotoxicity.
• To evaluate the in vivo tumor targeting and growth inhibition efficacy of NPs-cRGD.

Main Methods:

• Synthesis and characterization of PLGA-PEG-cRGD nanoparticles.
• Encapsulation of Au-Pt(IV), paclitaxel (PTX), and adriamycin (ADR) into NPs-cRGD.
• In vitro cell cycle analysis and cytotoxicity assays.
• In vivo tumor growth inhibition studies.

Main Results:

• Drug-loaded NPs-cRGD exhibited higher cytotoxicity compared to free drugs, linked to cell cycle arrest.
• Au-Pt(IV)@NPs-cRGD induced S and G0/G1 phase arrest, while PTX@NPs-cRGD and ADR@NPs-cRGD showed G2/M and S phase arrest, respectively.
• NPs-cRGD demonstrated efficient tumor accumulation and growth inhibition in vivo, correlating with in vitro findings.

Conclusions:

• Cell cycle arrest is a key mechanism for the enhanced efficacy of drug-loaded NPs-cRGD.
• Nanoparticle uptake is influenced by tumor cell nutrient status.
• Future nanomedicine research should incorporate cell cycle analysis to understand drug action mechanisms and optimize clinical applications.